Avyxa FDA Monday, November 9, 2026 +0.60 Positive

FDA Approves OXDERYS — Avyxa Pharma, LLC

Avyxa Pharma, LLC announced today that the FDA approved the NDA for OXDERYS (doxorubicin hydrochloride), a pivotal approval that is expected to make a significant impact on the oncology market by expanding the availability of this critical chemotherapeutic agent. This near-term launch position will likely bolster the company's revenue streams and intensify competition in a segment historically dominated by legacy products.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed